Live Breaking News & Updates on Michael Pehl

Stay updated with breaking news from Michael pehl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline

Raises additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors.Funds will be used to further strengthen growing pipeline of first in ....

Iyona Rajkomar , Michael Pehl , Healthcare Strategic Growth Fund , Novo Holdings , Dawn Biopharma , Managing Partner , Adcendo Board , Ysios Capital , Gilde Healthcare , Pontifax Venture , Development Candidate Nomination , Chief Executive Officer , Board Director , Pontifax Venture Capital , Strategic Growth Fund , Ihr Portfolio ,

Adcendo Raises €16M; Extends Series A to €98M

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time! ....

Michael Pehl , Iyona Rajkomar , Novo Holdings , Dawn Biopharma , Ysios Capital , Gilde Healthcare , Pontifax Venture , Managing Partner , Adcendo Board ,

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of. ....

Michael Pehl , Stage Clinical Development , Development Officer , Novo Holdings , Aarhus University , Global Oncology Development , Adcendo Aps , Chief Medical Officer , Global Clinical Head , Late Stage Clinical , Chief Development , Chief Executive Officer , Duality Biologics , Ysios Capital , Pontifax Venture Capital ,

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of. ....

John Zhu , Michael Pehl , Novo Holdings , Duality Biologics , Duality Immune Toxin Antibody Conjugates , Option License Agreement , Chief Executive Officer , Ysios Capital , Pontifax Venture Capital ,

Adcendo expands partnership with Duality Biologics

Adcendo has expanded its partnership with fellow biotech company Duality Biologics, in an effort to "broaden and expand" the collaboration. ....

Michael Pehl , John Zhu , Duality Immune Toxin Antibody Conjugates , Option License Agreement , Duality Biologics , Bio Developments , Markets Amp Regulations , Emerging Markets ,